Prelude Therapeutics
Clinical trials sponsored by Prelude Therapeutics, explained in plain language.
-
New drug combo shows promise for tough blood cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New drug targets Hard-to-Treat cancers with rare gene mutation
Disease control CompletedThis early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. 135 …
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC